140 related articles for article (PubMed ID: 8895744)
41. Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China.
Cao W; Chen X; Dai H; Wang H; Shen B; Chu D; McAfee T; Zhang ZF
Cancer; 2004 Aug; 101(4):834-44. PubMed ID: 15305417
[TBL] [Abstract][Full Text] [Related]
42. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
43. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
[TBL] [Abstract][Full Text] [Related]
44. Analysis of the anti-p53 antibody response in cancer patients.
Labrecque S; Naor N; Thomson D; Matlashewski G
Cancer Res; 1993 Aug; 53(15):3468-71. PubMed ID: 8339249
[TBL] [Abstract][Full Text] [Related]
45. Ethnicity delineates different genetic pathways in malignant glioma.
Chen P; Aldape K; Wiencke JK; Kelsey KT; Miike R; Davis RL; Liu J; Kesler-Diaz A; Takahashi M; Wrensch M
Cancer Res; 2001 May; 61(10):3949-54. PubMed ID: 11358811
[TBL] [Abstract][Full Text] [Related]
46. p53 antibodies in patients with various types of cancer: assay, identification, and characterization.
Lubin R; Schlichtholz B; Teillaud JL; Garay E; Bussel A; Wild CP
Clin Cancer Res; 1995 Dec; 1(12):1463-9. PubMed ID: 9815945
[TBL] [Abstract][Full Text] [Related]
47. [Serum anti-p53 antibodies in gastric cancer patients].
Lawniczak M; Bielicki D; Sulzyc-Bielicka V; Marlicz K; Starzyńska T
Pol Merkur Lekarski; 2007 Sep; 23(135):192-5. PubMed ID: 18080693
[TBL] [Abstract][Full Text] [Related]
48. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot.
Schlichtholz B; Legros Y; Gillet D; Gaillard C; Marty M; Lane D; Calvo F; Soussi T
Cancer Res; 1992 Nov; 52(22):6380-4. PubMed ID: 1423285
[TBL] [Abstract][Full Text] [Related]
49. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients.
Goan YG; Hsu HK; Chang HC; Chou YP; Chiang KH; Cheng JT
Ann Thorac Surg; 2005 Sep; 80(3):1007-16. PubMed ID: 16122475
[TBL] [Abstract][Full Text] [Related]
50. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer.
Tilkin AF; Lubin R; Soussi T; Lazar V; Janin N; Mathieu MC; Lefrère I; Carlu C; Roy M; Kayibanda M
Eur J Immunol; 1995 Jun; 25(6):1765-9. PubMed ID: 7615005
[TBL] [Abstract][Full Text] [Related]
51. [P53 antibodies: a new method for the analysis of alterations of the p53 gene: application to breast cancer].
Soussi T; Peyrat JP; Lubin R; Bonneterre J
Pathol Biol (Paris); 1996 Apr; 44(4):232-4. PubMed ID: 8763583
[TBL] [Abstract][Full Text] [Related]
52. Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia.
Preudhomme C; Lubin R; Lepelley P; Vanrumbeke M; Fenaux P
Leukemia; 1994 Sep; 8(9):1589-91. PubMed ID: 8090036
[TBL] [Abstract][Full Text] [Related]
53. TP53 gene mutation profile in esophageal squamous cell carcinomas.
Audrézet MP; Robaszkiewicz M; Mercier B; Nousbaum JB; Bail JP; Hardy E; Volant A; Lozac'h P; Charles JF; Gouéron H
Cancer Res; 1993 Dec; 53(23):5745-9. PubMed ID: 8242631
[TBL] [Abstract][Full Text] [Related]
54. Immunohistochemical study of p53 in human lung carcinomas.
Brambilla E; Gazzeri S; Moro D; Caron de Fromentel C; Gouyer V; Jacrot M; Brambilla C
Am J Pathol; 1993 Jul; 143(1):199-210. PubMed ID: 8317547
[TBL] [Abstract][Full Text] [Related]
55. Detection of serum anti-p53 antibodies from patients with ovarian cancer in China: correlation to clinical parameters.
Qiu T; Yang Q; Li XR; Yang H; Qiu LL; Wang L
Cancer Invest; 2007; 25(7):563-8. PubMed ID: 17952741
[TBL] [Abstract][Full Text] [Related]
56. p53 gene mutation in female genital tract carcinosarcomas (malignant mixed müllerian tumors): a clinicopathologic study of 74 cases.
Costa MJ; Vogelsan J; Young LJ
Mod Pathol; 1994 Aug; 7(6):619-27. PubMed ID: 7991520
[TBL] [Abstract][Full Text] [Related]
57. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface.
Lubin R; Schlichtholz B; Bengoufa D; Zalcman G; Trédaniel J; Hirsch A; Caron de Fromentel C; Preudhomme C; Fenaux P; Fournier G; Mangin P; Laurent-Puig P; Pelletier G; Schlumberger M; Desgrandchamps F; Le Duc A; Peyrat JP; Janin N; Bressac B; Soussi T
Cancer Res; 1993 Dec; 53(24):5872-6. PubMed ID: 8261396
[TBL] [Abstract][Full Text] [Related]
58. Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India.
Ralhan R; Arora S; Chattopadhyay TK; Shukla NK; Mathur M
Int J Cancer; 2000 Mar; 85(6):791-5. PubMed ID: 10709097
[TBL] [Abstract][Full Text] [Related]
59. Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer.
Shimada H; Okazumi S; Takeda A; Nabeya Y; Matsubara H; Funami Y; Hayashi H; Gunji Y; Suzuki T; Ochiai T
Surg Today; 2001; 31(7):591-6. PubMed ID: 11495153
[TBL] [Abstract][Full Text] [Related]
60. Circulating anti-p53 antibodies in esophageal cancer patients.
Kozłowski M; Kovalchuk O; Nikliński J; Chyczewski L; Starosławska E; Ciechański A; Dabrowski A; Niklińska W; Dziegielewski P; Lapuć G; Wallner G; Laudański J
Folia Histochem Cytobiol; 2001; 39 Suppl 2():173-4. PubMed ID: 11820593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
